Study guide

9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions

NABP MPJE Multistate Pharmacy Jurisprudence Examination Exam

Track your progress as you read

Finished sections get a check mark.

1 Chapter 1: Pharmacist Licensure & Reciprocity

1.1 Initial Licensure Requirements & Examinations 1.2 License Renewal, Continuing Education (CE) & Status 1.3 Reciprocity, License Transfer & Multistate Licensure 1.4 Disciplinary Actions, Board Hearings, Sanctions & Reinstatement

2 Chapter 2: Pharmacy Personnel Roles & Supervision Ratios

2.1 Pharmacy Interns: Scope of Practice, Supervision & Preceptor Rules 2.2 Pharmacy Technicians: Registration, Certification & Permitted Duties 2.3 Technician-to-Pharmacist Ratios & Delegated Tasks 2.4 Non-Pharmacist Personnel & Automated Dispensing Technology Roles

3 Chapter 3: Prescriptive Authority & Practitioner Categories

3.1 Physicians, Dentists, Veterinarians & Podiatrists: Prescribing Scope 3.2 Mid-Level Practitioners: APNs, PAs, Optometrists & Independent Authority 3.3 Out-of-State, Foreign & Deceased Practitioner Prescriptions 3.4 Self-Prescribing & Prescribing for Family Members

4 Chapter 4: Patient Counseling & Drug Utilization Review (OBRA '90)

4.1 OBRA '90 Mandates & Prospective Drug Utilization Review (DUR) 4.2 Patient Counseling Requirements, Offer-to-Counsel & Documentation 4.3 Patient Profile Requirements & Retrospective DUR

5 Chapter 5: Advanced Pharmacist Practice & Collaborative Agreements

5.1 Collaborative Practice Agreements (CPAs) & Protocol-Based Care 5.2 Pharmacist Immunization Authority & Vaccine Administration Protocols 5.3 Medication Therapy Management (MTM) & Point-of-Care Testing (POCT) 5.4 Hormonal Contraceptive, Naloxone & Post-Exposure Prophylaxis (PEP/PrEP) Prescribing

6 Chapter 6: Federal Controlled Substances Act (CSA) & Scheduling

6.1 Controlled Substance Schedules (CI through CV) & Classification Criteria 6.2 DEA Registration: Types, Forms (224, 225, 363) & Renewal Cycles 6.3 Scheduled Listed Chemical Products (SLCPs) & Combat Methamphetamine Epidemic Act (CMEA)

7 Chapter 7: Controlled Substance Prescriptions & Legitimate Purpose

7.1 Corresponding Responsibility & Red Flags for Improper Prescribing 7.2 Required Components of Controlled Substance Prescriptions 7.3 Electronic Prescriptions for Controlled Substances (EPCS) & Security Requirements 7.4 Emergency Schedule II Prescriptions & Partial Filling Rules (CARA Act)

8 Chapter 8: Controlled Substance Ordering, Inventory & Recordkeeping

8.1 Ordering Schedule II Substances: CSOS & DEA Form 222 Execution 8.2 Controlled Substance Inventory Requirements (Initial, Biennial, Count Exactness) 8.3 Theft, Significant Loss (DEA Form 106) & Disposal/Destruction (DEA Form 41) 8.4 Prescription Transfers & Prescription Drug Monitoring Programs (PDMPs)

9 Chapter 9: Federal Pure Food, Drug & Cosmetic Act (FD&C Act) & Drug Safety

9.1 Adulteration vs. Misbranding: Statutory Definitions & Legal Violations 9.2 Prescription Labeling Requirements, Expiration Dates & Side Effect Statements 9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions 9.4 Drug Recalls (Class I, II, III) & Market Withdrawals 9.5 Drug Product Selection, Generic Substitution & DAW Codes 9.6 Returning & Reusing Dispensed Drugs: Restocking, Redispensing & Repository Programs

10 Chapter 10: Drug Supply Chain Security Act (DSCSA) & Commercial Distribution

10.1 DSCSA Track-and-Trace Requirements: Transaction Information & Statements 10.2 Suspect & Illegitimate Product Verification, Quarantine & Notification 10.3 Prescription Drug Marketing Act (PDMA): Samples, Reimportation & Wholesale Distribution

11 Chapter 11: Compounding Standards: USP <795>, <797> & <800>

11.1 Section 503A vs. 503B Compounding Facilities (DQSA Architecture) 11.2 Non-Sterile Compounding (USP <795>) & Beyond-Use Dating (BUD) 11.3 Sterile Compounding (USP <797>): Air Quality, Cleanrooms & BUD 11.4 Hazardous Drug Handling (USP <800>): Engineering Controls & Personal Protective Equipment

12 Chapter 12: Pharmacy Operational Security, Records & Telepharmacy

12.1 Physical Pharmacy Security, Alarm Systems & Keyholder Rules 12.2 Mandatory Pharmacy Records Retention & Audit Inspection Readiness 12.3 Central Fill, Automated Dispensing Systems (ADS) & Telepharmacy Operations 12.4 HIPAA Privacy Rule, Patient Records & Breach Notification Protocols

9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions

Key Takeaways Explain This Topic AI

The Poison Prevention Packaging Act (PPPA) of 1970 is administered and enforced by the Consumer Product Safety Commission (CPSC), not the FDA.

Child-resistant packaging standards require that 80% of tested children under 5 years cannot open the container within 10 minutes, while 90% of adults aged 50–70 can open and reclose it within 5 minutes.

Patients may request a blanket waiver (verbal or written) for non-child-resistant packaging on all current and future prescriptions, while prescribers can only request single-fill waivers.

Plastic prescription vials and plastic closures CANNOT be reused on refills; glass vials may be reused only if a brand-new plastic closure is provided.

Sublingual nitroglycerin, sublingual/chewable isosorbide dinitrate (<=10mg), oral contraceptives in memory packs, and Medrol Dosepaks (<=84mg) are statutorily exempt from PPPA packaging rules.

Last updated: July 2026

9.3 Poison Prevention Packaging Act (PPPA) & Child-Resistant Container Exemptions

MPJE Core Concept: The Poison Prevention Packaging Act (PPPA) of 1970 was enacted to safeguard young children from accidental ingestion of toxic household chemicals and prescription legend drugs. Candidates must know the enforcing agency (CPSC), technical packaging test effectiveness standards, strict restrictions on container reuse, rules governing patient and prescriber waivers, and the exact statutory list of drug exemptions.

1. Enforcing Agency & Legal Scope

Enforcing Regulatory Authority: The PPPA is enforced by the Consumer Product Safety Commission (CPSC) . It is NOT enforced by the FDA or DEA. (MPJE trick questions frequently test this administrative distinction).

Scope of Coverage: Applies to all oral human prescription drugs, liquid and solid dosage forms, as well as designated hazardous OTC household substances (such as aspirin, liquid methyl salicylate >5%, iron-containing supplements >250 mg elemental iron, diphenhydramine >66 mg, ibuprofen >1 g, naproxen >250 mg, and loperamide >0.045 mg).

Exempted Dosage Forms: Non-oral dosage forms—such as topical creams/ointments, eye drops, ear drops, nasal sprays, and inhalers—are automatically exempt from PPPA child-resistant packaging requirements because they are not intended for oral administration.

2. Technical Child-Resistant Effectiveness Testing Standards

To be certified as child-resistant , a container design must undergo rigorous panel testing mandated by CPSC protocol regulations:

Child Testing Panel Standard: A test panel of children under 5 years of age (42–54 months old) is given the packaging. At least 80% of children must be unable to open the container within 10 minutes of testing (or within 5 minutes prior to a visual demonstration).

Adult Senior Panel Standard: A test panel of adults aged 50 to 70 years old is given the container. At least 90% of adults must be able to open and properly reclose the container within 5 minutes on their first attempt, and within 1 minute on subsequent attempts.

3. Container Reuse Restrictions on Prescription Refills

When refilling a prescription, pharmacists must comply with strict physical container reuse regulations to prevent mechanical wear and tear from degrading safety closure performance:

All-Plastic Prescription Vials & Closures: A pharmacist CANNOT reuse plastic vials or plastic safety closures when dispensing a refill. Both the plastic body and the plastic cap must be discarded and replaced with a new vial and new cap upon every fill.

Glass Containers: Glass prescription vials may be reused upon refill ONLY IF a brand-new plastic safety closure/cap is used. (The glass body does not wear down, but the plastic threading on the cap degrades).

Unit-Dose & Blister Packaging: Package designs where the container and closure are integral (e.g., unit-dose blister cards, memory packs) cannot be reused.

4. Waiver and Opt-Out Regulations: Patient vs. Prescriber

The PPPA permits exemptions from child-resistant packaging upon request, but strict legal differences separate patient waivers from prescriber waivers:

Waiver Parameter Patient Request Prescriber Request

Scope of Waiver Can request a blanket waiver covering ALL future prescriptions dispensed at that pharmacy. Can request non-child-resistant caps ONLY on a per-prescription basis (single order/fill).

Form of Request Can be requested verbally or in writing . (Written, signed documentation is strongly recommended for pharmacy risk management). Included on the written/electronic prescription order, or communicated verbally during order transmission.

Revocation & Renewal Patient can revoke a blanket waiver at any time. Blanket waivers do not expire automatically unless revoked. Prescribers CANNOT issue a blanket waiver for all of a patient's prescriptions. Each new Rx requires a separate request.

Pharmacy Documentation Pharmacy should document blanket waiver preference in the patient's electronic profile and sign periodic confirmations. Pharmacy must document the single-fill request on the specific prescription record.

5. Complete Statutory List of Exemptions from PPPA Packaging

Congress and the CPSC have established explicit statutory exemptions for specific legend drugs where immediate, uninhibited patient access is vital for emergency medical care, or where packaging design makes child-resistant closures impractical. Candidates must memorize this complete MPJE statutory list:

Sublingual Nitroglycerin (SL NTG): All dosage strengths of sublingual nitroglycerin tablets (critical for immediate treatment of acute angina attacks).

Isosorbide Dinitrate: Sublingual and chewable forms in dosage strengths of 10 mg or less .

Erythromycin Ethylsuccinate (EES):

Oral suspensions and granules for oral suspension in package sizes containing no more than 8 grams of erythromycin.

EES tablets in package sizes containing no more than 16 grams of erythromycin.

Anhydrous Cholestyramine: Powder formulations packaged in individual packets.

Potassium Supplements: Unit-dose forms (effervescent tablets, liquid unit-doses, and dry powder packets) containing no more than 50 mEq of potassium per dose.

Sodium Fluoride: Liquid and tablet preparations containing no more than 264 mg of sodium fluoride per package.

Betamethasone Tablets: Package sizes containing no more than 12.6 mg of betamethasone.

Mebendazole Tablets: Package sizes containing no more than 600 mg of mebendazole.

Methylprednisolone Tablets: Package sizes containing no more than 84 mg of methylprednisolone (e.g., standard 4-day or 6-day Medrol Dosepak).

Colestipol Powder: Packaged in individual packets containing no more than 5 grams of colestipol.

Pancrelipase Preparations: All tablet, capsule, or powder formulations of pancrelipase.

Oral Contraceptives & Conjugated Estrogens: Dispensed in manufacturer unit-of-use memory-aid dispenser packages (e.g., 28-day dial-packs).

Prednisone Tablets: Package sizes containing no more than 105 mg of prednisone.

Sacrosidase (Sucrase) Preparations: Formulations in 3.2% glycerol and water.

Hormone Replacement Therapy (HRT): Products relying solely on one or more progestogen or estrogen substances.

Institutional Exception (Inpatient Hospital & Long-Term Care)

Drugs dispensed to institutionalized inpatients (e.g., hospital patients, nursing home residents) are exempt from PPPA child-resistant packaging requirements, provided that the medications are maintained in institutional stock and administered exclusively by licensed healthcare personnel (nurses, physicians).

Loading diagram... PPPA Child-Resistant Packaging Exemption & Waiver Decision Tree